
ACMG Education Webinar Series: Translating Genes into Health® On-Demand
Date of Release: February 1, 2026
Expiration Date: February 29, 2028
P.A.C.E.® credits valid through February 28, 2027
Credits offered: 10.0 AMA PRA Category 1 Credits™, P.A.C.E.®
Estimate time of completion: 10 hours
Specialized events developed by ACMG Committees.
Course Description
The ACMG Webinar Series: Translating Genes into Health® is a collaborative educational initiative designed to showcase the expertise and contributions of ACMG committees while addressing emerging and impactful topics in medical genetics and genomics. This series provides a platform for thought leaders, researchers, and clinicians to engage in meaningful discussions on advancements in genetic testing, clinical applications, ethical considerations, and health equity.
Through interactive, expert-led sessions, participants will gain valuable insights into cutting-edge research, translational genomics, and best practices in patient care. Each session is developed in collaboration with ACMG committees, reflecting their ongoing efforts to shape the future of clinical genetics through education, policy, and innovation.
Course Registration Fees
|
Category
|
Member Fee
|
Non-Member Fee
|
|
Professional
|
$0
|
$35
|
|
Postdoc/Trainee/Student
|
$0
|
$35
|
Webinar Series Topics:
- January 10, 2026, Gene Therapy Bootcamp – Application in Neurodevelopmental Disorder
- February 17, 2026, The Horizon of Prenatal Therapies for Genetic Disorders
By attending this series, healthcare professionals will enhance their ability to interpret and apply genetic and genomic data in clinical practice, navigate ethical considerations, and leverage funding opportunities to support patient-centered research and care. This initiative underscores ACMG’s commitment to advancing genetics and genomics education while fostering collaboration across its diverse committee network.
Target Audience
This activity is designed for clinical geneticists, genetic counselors, laboratory professionals, and other healthcare providers involved in the diagnosis and management of genetic conditions. The content is also relevant to researchers and healthcare professionals seeking to stay up to date on emerging advancements and best practices in genetic conditions.
Learning Objectives
At the conclusion of this series, participants should be able to:
- Apply the latest advancements in clinical genetics and genomics to improve patient care, including innovations in gene therapy, diagnostic transcriptome RNA sequencing, and variant classification.
- Evaluate funding opportunities from the Patient-Centered Outcomes Research Institute (PCORI) and identify strategies for supporting historically underserved patient populations through research initiatives.
- Interpret complex genetic findings and assess their clinical utility, limitations, and implications for patient management.
- Analyze ethical principles and challenges in genetic and genomic medicine, ensuring responsible and equitable application of genetic testing and counseling.
- Engage with ACMG committees to gain insights into emerging research, best practices, and collaborative efforts that shape the future of medical genetics and genomics.
Planners
Henry J. Mroczkowski, MD, PhD, FACMG (Chair)
University of TN Health Science Ctr
Mari Mori, MD, MS, FACMG
The Ohio State University
Georgianne L. Arnold, MD, FACMG
University of Pittsburgh
Roya M. Mostafavi, MGC
University of Washington School of Medicine
Catherine A. Ziats, MD, FACMG
Cook Children's
Damara Ortiz, MD, FACMG
Children's Hospital of Pittsburgh of UPMC
Daniel Schecter, MD, MS
Mount Sinai School of Medicine
Staff
Jane Radford, MHA, CHCP
Director of Education
Claudia Barnett
Senior Program Coordinator
 |
Moderator: Mari Mori, MD, FACMG The Ohio State University
|
 |
Presenter: Maya Chopra, MD
Harvard Medical School
|
 |
Presenter: Toni Pearson, MD
Nationwide Children’s Hospital
|
 |
Moderator: Roya Mostafavi, MS, CGC
University of Washington School of Medicine
|
 |
Presenter: Billie Lianoglou, CGC
University of California, San Francisco
|
 |
Presenter: Richard Finkel, MD
St. Jude Children’s Research Hospital
|
ACMG Accredited Continuing Education Information
Accredited Continuing Education Information:
AMA PRA Category 1 Credits™, P.A.C.E.®
Accreditation
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.
ASCLS P.A.C.E.® CEU's
ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program.
ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider (50-11878). ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.® (275-200-26). This activity has been approved for 0.10 P.A.C.E.® CEU's.
Claiming your Educational Credits
This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit. If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.
Learner Data Consent
ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.
Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.
Accredited Continuing Education Financial Disclosure
The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.
ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
ACMG Education Policies
Please review the policies below regarding the ACMG Education program

All of the relevant financial relationships listed for these individuals have been mitigated.
|
Name
|
Role
|
Relationship/Company
|
|
Maya Chopra, MD
|
CE Presenter
|
No Relevant Financial Relationships
|
|
Toni Pearson, MD
|
CE Presenter
|
No Relevant Financial Relationships
|
|
Roya Mostafavi, MS, CGC
|
Moderator, Planner
|
No Relevant Financial Relationships
|
|
Billie Lianoglou, CGC
|
CE Presenter
|
No Relevant Financial Relationships
|
|
Richard Finkel, MD
|
CE Presenter
|
Consultant: Astellas Pharma, Biogen, Dyne Therapeutics, F. Hoffmann-La Roche, Genentech, Inc., italfarmaco (ended 12/31/2024), Novartis, NS Pharma, ReveraGen (ended 12/31/2025), Sarepta Therapeutics, Inc., Satellos (ended 12/31/2025), Scholar Rock
Research Grant: Dyne Therapeutics, italfarmaco (ended 12/31/2024), Novartis, Sarepta Therapeutics, Inc., Scholar Rock
DSMB: Gemma Biotherapeutics, Ionis Pharmaceuticals, Solid Biosciences
|
|
Mari Mori, MD, MS, FACMG
|
Moderator, Planner
|
Research Grant(ended 11/2024): HemoShear Therapeutics
Research Grant (ended 7/2024): Sanofi and Genzyme US Companies
|
|
Henry J. Mroczkowski, MD, PhD, FACMG
|
Planner, Moderator
|
No Relevant Financial Relationships
|
|
Georgianne L. Arnold, MD, FACMG
|
Planner
|
No Relevant Financial Relationships
|
|
Roya M. Mostafavi, MGC
|
Planner
|
No Relevant Financial Relationships
|
|
Catherine A. Ziats, MD, FACMG
|
Planner
|
No Relevant Financial Relationships
|
|
Damara Ortiz, MD, FACMG
|
Planner
|
Research Grant: Amicus Therapeutics, Freeline Therapeutics, GC Biopharma, Sanofi and Genzyme US Companies, Uniqure
|
|
Daniel Schecter, MD, MS
|
Planner
|
No Relevant Financial Relationships
|
|
Jane Radford, MHA, CHCP
|
Staff
|
No Relevant Financial Relationships
|
|
Claudia Barnett
|
Staff
|
No Relevant Financial Relationships
|